"Age-related dysfunction is unlikely to arise from a single universal mechanism."
BUFFALO, NY — November 3, 2026 — A new review was published in Volume 18 of Aging on October 9, 2026, titled " The polycentric aging framework: epigenetic regulation as a dominant lifespan-limiting center in human aging ."
The review introduces the Polycentric Aging Framework (PAF), which proposes that aging results from several interacting biological processes rather than a single universal mechanism. Drawing on evidence from cellular reprogramming, DNA methylation, metabolic signaling and human intervention studies, the authors suggest that epigenetic regulation may be a dominant, but not exclusive, factor limiting human lifespan. The framework offers a new perspective on how different aging mechanisms interact and how targeted interventions might help preserve biological function.
The review was authored by first and corresponding author Michał Bartoszewicz, an independent researcher based in Warsaw, Poland, and co-author and corresponding author Mariusz Niemczyk, affiliated with the Medical University of Warsaw .
Aging involves interconnected changes, including genomic instability, mitochondrial dysfunction, cellular senescence, impaired protein maintenance and declining regenerative capacity. Although these processes contribute to age-related deterioration, their relative importance in determining lifespan remains uncertain. Understanding their interactions may help researchers identify strategies to extend healthspan, the period of life spent in good health.
The Polycentric Aging Framework organizes these processes into partially independent but interacting biological centers. Each differs in its timing, reversibility, influence on other systems and potential to limit lifespan. The authors propose that targeting one mechanism may improve function, but another biological constraint could subsequently become limiting, suggesting that effective interventions may need to address several processes over time.
The framework identifies three major constraint layers: epigenetic regulation, irreversible genetic and physical damage, and the accumulation of damaged proteins and organelles. These interact with telomere dynamics, mitochondrial metabolism, stem-cell function, cellular senescence and systemic signaling.
Epigenetic regulation is proposed as particularly influential because it controls gene expression without altering the underlying DNA sequence. Through DNA methylation, histone modifications and chromatin remodeling, it regulates cellular identity, metabolism, stress responses and tissue maintenance. With age, some epigenetic changes may contribute to dysfunction, while others represent protective responses to stress or accumulated damage.
An important foundation for this hypothesis comes from somatic cell nuclear transfer (SCNT), the technique used to create cloned animals. By transferring a differentiated cell nucleus into an egg cell whose nucleus has been removed, researchers can restore developmental potential and extensively reprogram selected aging-associated molecular states.
Successful cloning experiments demonstrate that nuclei from aged cells can support the development of organisms with species-typical lifespan potential. However, cloning does not rejuvenate an existing individual or eliminate all biological damage. Epigenetic states appear particularly responsive to reprogramming, while telomere length, mitochondrial function and protein maintenance show more variable responses. Established DNA mutations and structural abnormalities generally remain, helping explain why extended serial cloning eventually encounters genetic limitations.
The framework also reconsiders telomere shortening as an important checkpoint rather than a universal primary cause of aging. This interpretation draws partly on the hyperfunction theory developed by Mikhail Blagosklonny, which proposes that biological programs beneficial during development can become harmful when their activity persists or becomes maladaptive later in life.
Mitochondrial dysfunction is another important component. Mitochondria provide energy and metabolites that influence epigenetic regulation, while nuclear gene-expression programs control mitochondrial maintenance. These interactions can reinforce inflammation, cellular senescence and metabolic dysfunction, creating feedback mechanisms that contribute to aging.
Similarly, senescent cells can accumulate with age and release inflammatory molecules through the senescence-associated secretory phenotype (SASP). Although senescence initially protects against uncontrolled cell proliferation, persistent senescent cells may amplify tissue dysfunction. Hormones, immune signaling and extracellular vesicles further influence how these processes interact across different tissues.
Another major focus is DNA methylation clocks, which estimate biological age or the pace of aging from patterns of DNA methylation. Although increasingly used in aging research, the authors caution that lower epigenetic age estimates do not necessarily demonstrate rejuvenation.
The review distinguishes potentially harmful epigenetic changes, described as Type 1, from adaptive or compensatory responses, described as Type 2. Current clocks may not reliably differentiate these categories. Consequently, an intervention could lower estimated biological age without improving physiological function or resilience. The authors emphasize evaluating clock measurements alongside health outcomes, disease risk and mortality.
The review also examines human intervention studies. In the two-year CALERIE randomized trial involving 220 adults without obesity, caloric restriction slowed the estimated pace of aging measured by DunedinPACE but did not significantly change several other epigenetic age measures.
Other research, including the DO-HEALTH trial, reported modest reductions in selected DNA methylation-based age estimates following omega-3 supplementation, with additional effects from combining certain interventions. Smaller studies involving dietary changes, exercise and metabolic treatments have also reported alterations in epigenetic age estimates. However, these findings do not establish that such interventions extend human lifespan.
Beyond lifestyle interventions, the authors examine molecular pathways involving insulin-like growth factor-1 (IGF-1), mTOR, AMPK and sirtuins. These interconnected networks regulate cellular growth, metabolism and stress adaptation. Caloric restriction, exercise and selected pharmacological agents can influence these pathways, although their effects depend on biological context.
The review also explores partial cellular reprogramming using factors such as OCT4, SOX2 and KLF4. Experimental studies have shown improvements in selected aging-related molecular and functional measures, with some animal experiments reporting extended survival. However, uncontrolled reprogramming can disrupt cellular identity and increase the risk of abnormal growth or tumors, making safety a major barrier to clinical application.
Other potential strategies include senolytic treatments aimed at eliminating persistent senescent cells and interventions targeting metabolic dysfunction, inflammation and systemic signaling. The framework suggests that combining approaches may eventually be more effective than targeting individual mechanisms, particularly when the biological constraints limiting function differ between tissues or life stages.
"Future progress in aging research will likely depend on integrating mechanistic insight, functional outcomes, and carefully validated biomarkers within frameworks that account for the heterogeneity of aging mechanisms."
The review emphasizes that successful treatment may depend on identifying which aging process is limiting function in a particular individual or tissue. Improving epigenetic regulation alone may offer limited benefits if irreversible genetic damage, impaired regeneration or accumulated cellular waste has already become the dominant constraint.
However, the Polycentric Aging Framework remains a conceptual model rather than an experimentally validated explanation of human aging. The evidence comes from diverse experimental systems and clinical studies, and the proposed dominance of epigenetic regulation has not been conclusively established in humans. Future research will require longitudinal studies, controlled interventions, validated biomarkers and meaningful functional outcomes.
Safety also remains essential. Treatments involving epigenetic reprogramming, genetic modification or multiple interacting pathways may introduce cancer-related and other adverse risks. The authors emphasize prioritizing preservation of health and physiological function over pursuing extreme lifespan extension without sufficient safety evidence.
Overall, the review presents aging as a dynamic interaction among several biological constraints, with epigenetic regulation proposed as a particularly influential but not exclusive component. By distinguishing potentially reversible regulatory changes from more persistent cellular damage, the framework offers new directions for investigating how targeted and combined interventions might preserve function and support healthy longevity.
Paper DOI: https://doi.org/10.18632/aging.206426
